Expanded Access and Post-Trial Access: Supplying Patients Outside the Trial

Every clinical supply chain is built around a protocol. Expanded access and post-trial access programs ask that same supply chain to serve patients who aren't in the protocol — one at a time, in countries you may not have trial sites in, through physicians who may never have handled investigational product, for as long as the patient keeps benefiting.

These programs matter enormously to the patients they serve, and increasingly to regulators, ethics committees, and patient advocacy groups. They also generate some of the most unpredictable demand a supply team will ever face. Here's how to design supply that holds up.

What's the difference between expanded access and post-trial access?

They're related but distinct:

• Expanded access (often called compassionate use, early access, or managed access) gives patients who can't enroll in a trial access to an investigational drug outside of it, usually for serious or life-threatening conditions with no satisfactory alternative. In the US this runs under FDA's expanded access provisions — individual patient, intermediate-size population, and treatment protocols. In the EU, member states operate compassionate use programmes and national named-patient routes under their own rules.
• Post-trial access means continuing to provide the investigational treatment to trial participants after their study ends, when they're benefiting and the product isn't otherwise available to them. Ethical frameworks, including the Declaration of Helsinki, expect sponsors to plan for this.

Both share the same supply profile: small, irregular, long-running demand, outside the clinical trial infrastructure.

Why is expanded access supply so hard?

Because it strips away almost everything that makes trial supply manageable:

• No enrollment curve. Requests arrive one physician at a time, often unpredictably and often urgently.
• No established sites. Product may need to reach a hospital pharmacy in a country with no trial presence, no import history, and no trained staff.
• No IRT. Many programs run without the randomization and inventory system that automates trial resupply.
• Country-by-country regulation. Each country has its own approval route, import permit, and documentation requirements — and the paperwork is often patient-specific. Our customs and import guide covers the border side.
• Open-ended duration. A patient who benefits may stay on drug for years.
• Competition for scarce supply. Access demand draws on the same limited inventory as ongoing trials. In rare disease supply, a single program can threaten trial continuity if not ring-fenced.

How should sponsors design an access program's supply model?

Start with policy, then build supply to match it:

1. Define eligibility and capacity before demand arrives. A published access policy — which patients, which countries, what criteria — isn't just an ethics requirement. It's the only way to bound supply demand. Decide how much inventory can be allocated to access without jeopardising trials, and what happens when that allocation is reached.

2. Choose the supply source deliberately. Access product might come from clinical inventory (fast, but competes with trials and carries clinical labels), dedicated access batches (clean separation, but needs its own planning and stability), or eventually commercial product. Each choice affects labeling, release, and accountability.

3. Choose a distribution model. Many sponsors use a specialist early-access or named-patient provider that already holds import know-how, country relationships, and physician support processes. Others run it through the clinical depot network. The right answer depends on program scale and geographic spread.

4. Design labeling and documentation for non-trial settings. Instructions must work for physicians and pharmacists who've never seen the protocol. Patient-specific import permits, physician requests, and approvals need a tracked workflow.

5. Keep accountability intact. Product dispensed outside a trial still needs traceability from release to final disposition — including returns and reconciliation — and adverse events still need a reporting path.

How do you forecast demand for access programs?

Imperfectly — which is why capacity limits matter. Useful inputs include:

• The number of patients screened out of, or unable to reach, the trials.
• Physician and patient-organisation interest signals.
• For post-trial access, the number of participants expected to be benefiting at each study's end, and their projected duration on treatment — the same long-tail logic as an oncology treat-until-progression tail.
• Expected approval and reimbursement dates by country, which determine when access patients can move to commercial supply.

Model scenarios, set a ring-fenced allocation, and review it monthly against actual requests.

How does an access program end?

Every access program needs an exit plan from day one. Most end with a transition to commercial product once the drug is approved and reimbursed in the patient's country — which can be years apart across markets. Some end when development stops, which raises hard ethical questions about patients who are benefiting. Plan the transition country by country as part of the wider clinical-to-commercial transition, and communicate it to physicians well in advance.